We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge
Read MoreHide Full Article
Shares of INNOVATE Corp. (VATE - Free Report) have gained 5.3% since reporting second-quarter 2026 results, outperforming the S&P 500 index’s 0.5% return. However, over the past month, the stock has declined 14.8%, while the index has advanced 4.1%.
Earnings & Revenue Performance
Second-quarter revenues rose 74.2% to $421.6 million from $242 million in the prior-year quarter. Net income attributable to common stockholders and participating preferred stockholders was $10.4 million, reversing a $22-million loss. At the same time, earnings were 71 cents per share against a loss of $1.67 per share in the prior-year quarter. Total adjusted EBITDA increased 194.9% to $46.3 million from $15.7 million. Gross profit climbed to $79.5 million from $45.6 million, and operating income increased to $34.5 million from $4.9 million.
Infrastructure revenues advanced 77.6% to $414 million from $233.1 million, with segment net income rising to $26.4 million from $5.5 million, and adjusted EBITDA to $48.7 million from $19.3 million. The gross margin improved about 60 basis points to 18.5%, while the adjusted EBITDA margin expanded about 350 basis points to 11.8%. As of June 30, reported backlog was $1.9 billion and adjusted backlog, including awarded but unsigned contracts, was $2.7 billion compared with $1.7 billion and $1.8 billion, respectively, as of Dec. 31, 2025.
Life Sciences revenues fell 31.3% to $2.2 million from $3.2 million in the prior-year quarter, though its adjusted EBITDA loss narrowed to $0.8 million from $2.6 million. R2 Technologies generated $3.6 million in demand and ended with 110 systems in backlog, representing $1.4 million in future revenues. Spectrum revenues eased to $5.4 million from $5.7 million, and adjusted EBITDA declined to $0.4 million from $1 million. Excluding restricted and held-for-sale amounts, cash fell to $87.8 million from $108.2 million at the year-end, while total principal debt increased to $626.4 million from $617.5 million.
Management Commentary
Interim CEO Paul Voigt characterized DBM Global’s quarter as record-breaking, citing execution and backlog growth. Management identified data centers, technology, healthcare and New York City as activity drivers, alongside investment in artificial intelligence infrastructure, semiconductors, advanced manufacturing, energy systems and digital connectivity. Voigt said that MediBeacon was engaged with more than 100 healthcare institutions about its TGFR kidney-function system, while R2 was expanding and using lower costs to improve operating leverage.
Factors Influencing Headline Numbers
The revenue increase mainly reflected the timing and scale of large structural-steel projects at DBMG, together with revisions to cost-to-complete estimates arising from project efficiencies. Construction modeling, detailing and the new modular business also contributed, while industrial maintenance and repair activity declined as prior-year projects were completed. Life Sciences was pressured by fewer Glacial fx units in North America and Glacial Spa units internationally because of liquidity constraints. Spectrum was affected by terminated networks and markets, partly offset by launches.
Net income benefited from a $33.9-million increase in gross profit and an $18.7-million year-over-year improvement in gains on debt extinguishment. Those benefits were partly offset by increases of $8.9 million in tax expenses, $6.4 million in selling, general and administrative expenses, and $6.2 million in interest expenses. Higher taxes reflected stronger pretax income and limits on use of net operating losses.
Management Outlook
Management said DBMG’s backlog supports visibility into 2027 and 2028 and pointed to a robust second-half project pipeline, while emphasizing capacity discipline and margin preservation. R2 entered the second half with strong demand but was seeking additional capital for inventory, manufacturing scale-up and commercial expansion. MediBeacon targets a pivotal study of its third-generation wireless TGFR sensor in 2027 and a European Lumitrace marketing-authorization filing that year.
Other Developments
Broadcasting completed a $105-million refinancing used to retire 8.50% and 11.45% notes, repurchase certain equity interests and cover transaction costs. INNOVATE also agreed to sell CONX Corp. an approximately 75% controlling interest in Broadcasting, retaining about 25%, subject to FCC and other approvals. Management said that the refinancing loan is expected to be extinguished at closing and CONX has committed up to $75 million in post-closing equity. INNOVATE continued a sale process for substantially all DBMG assets or equity. After quarter-end, R2 extended a secured-note maturity from Aug. 1 to Dec. 31, 2026, and converted preferred equity to common equity.
View the Zacks #1 Rank List
Image: Bigstock
VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge
Shares of INNOVATE Corp. (VATE - Free Report) have gained 5.3% since reporting second-quarter 2026 results, outperforming the S&P 500 index’s 0.5% return. However, over the past month, the stock has declined 14.8%, while the index has advanced 4.1%.
Earnings & Revenue Performance
Second-quarter revenues rose 74.2% to $421.6 million from $242 million in the prior-year quarter. Net income attributable to common stockholders and participating preferred stockholders was $10.4 million, reversing a $22-million loss. At the same time, earnings were 71 cents per share against a loss of $1.67 per share in the prior-year quarter. Total adjusted EBITDA increased 194.9% to $46.3 million from $15.7 million. Gross profit climbed to $79.5 million from $45.6 million, and operating income increased to $34.5 million from $4.9 million.
INNOVATE Corp. Price, Consensus and EPS Surprise
INNOVATE Corp. price-consensus-eps-surprise-chart | INNOVATE Corp. Quote
Other Key Business Metrics
Infrastructure revenues advanced 77.6% to $414 million from $233.1 million, with segment net income rising to $26.4 million from $5.5 million, and adjusted EBITDA to $48.7 million from $19.3 million. The gross margin improved about 60 basis points to 18.5%, while the adjusted EBITDA margin expanded about 350 basis points to 11.8%. As of June 30, reported backlog was $1.9 billion and adjusted backlog, including awarded but unsigned contracts, was $2.7 billion compared with $1.7 billion and $1.8 billion, respectively, as of Dec. 31, 2025.
Life Sciences revenues fell 31.3% to $2.2 million from $3.2 million in the prior-year quarter, though its adjusted EBITDA loss narrowed to $0.8 million from $2.6 million. R2 Technologies generated $3.6 million in demand and ended with 110 systems in backlog, representing $1.4 million in future revenues. Spectrum revenues eased to $5.4 million from $5.7 million, and adjusted EBITDA declined to $0.4 million from $1 million. Excluding restricted and held-for-sale amounts, cash fell to $87.8 million from $108.2 million at the year-end, while total principal debt increased to $626.4 million from $617.5 million.
Management Commentary
Interim CEO Paul Voigt characterized DBM Global’s quarter as record-breaking, citing execution and backlog growth. Management identified data centers, technology, healthcare and New York City as activity drivers, alongside investment in artificial intelligence infrastructure, semiconductors, advanced manufacturing, energy systems and digital connectivity. Voigt said that MediBeacon was engaged with more than 100 healthcare institutions about its TGFR kidney-function system, while R2 was expanding and using lower costs to improve operating leverage.
Factors Influencing Headline Numbers
The revenue increase mainly reflected the timing and scale of large structural-steel projects at DBMG, together with revisions to cost-to-complete estimates arising from project efficiencies. Construction modeling, detailing and the new modular business also contributed, while industrial maintenance and repair activity declined as prior-year projects were completed. Life Sciences was pressured by fewer Glacial fx units in North America and Glacial Spa units internationally because of liquidity constraints. Spectrum was affected by terminated networks and markets, partly offset by launches.
Net income benefited from a $33.9-million increase in gross profit and an $18.7-million year-over-year improvement in gains on debt extinguishment. Those benefits were partly offset by increases of $8.9 million in tax expenses, $6.4 million in selling, general and administrative expenses, and $6.2 million in interest expenses. Higher taxes reflected stronger pretax income and limits on use of net operating losses.
Management Outlook
Management said DBMG’s backlog supports visibility into 2027 and 2028 and pointed to a robust second-half project pipeline, while emphasizing capacity discipline and margin preservation. R2 entered the second half with strong demand but was seeking additional capital for inventory, manufacturing scale-up and commercial expansion. MediBeacon targets a pivotal study of its third-generation wireless TGFR sensor in 2027 and a European Lumitrace marketing-authorization filing that year.
Other Developments
Broadcasting completed a $105-million refinancing used to retire 8.50% and 11.45% notes, repurchase certain equity interests and cover transaction costs. INNOVATE also agreed to sell CONX Corp. an approximately 75% controlling interest in Broadcasting, retaining about 25%, subject to FCC and other approvals. Management said that the refinancing loan is expected to be extinguished at closing and CONX has committed up to $75 million in post-closing equity. INNOVATE continued a sale process for substantially all DBMG assets or equity. After quarter-end, R2 extended a secured-note maturity from Aug. 1 to Dec. 31, 2026, and converted preferred equity to common equity.